Catalyst
Slingshot members are tracking this event:
FDA points to deficiencies within Axsome's (AXSM) AXS-05 regulatory application. Final decision on AXS-05's regulatory review for Major Depressive Disorder postponed for Aug. 22, 2021
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AXSM |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 23, 2021
Occurred Source:
https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-provides-update-new-drug-application-axs-05
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Axs-05, Major Depressive Disorder
